185 related articles for article (PubMed ID: 36499504)
1. Direct In Vivo Comparison of
Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504
[TBL] [Abstract][Full Text] [Related]
2. Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [
Bragina O; Chernov V; Schulga A; Konovalova E; Hober S; Deyev S; Sörensen J; Tolmachev V
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370758
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of
Bragina O; von Witting E; Garousi J; Zelchan R; Sandström M; Orlova A; Medvedeva A; Doroshenko A; Vorobyeva A; Lindbo S; Borin J; Tarabanovskaya N; Sörensen J; Hober S; Chernov V; Tolmachev V
J Nucl Med; 2021 Apr; 62(4):493-499. PubMed ID: 32817142
[TBL] [Abstract][Full Text] [Related]
4. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
[TBL] [Abstract][Full Text] [Related]
5. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
[TBL] [Abstract][Full Text] [Related]
6. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
7. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of
Bragina O; Chernov V; Schulga A; Konovalova E; Garbukov E; Vorobyeva A; Orlova A; Tashireva L; Sörensen J; Zelchan R; Medvedeva A; Deyev S; Tolmachev V
J Nucl Med; 2022 Apr; 63(4):528-535. PubMed ID: 34385343
[TBL] [Abstract][Full Text] [Related]
9. Optimal composition and position of histidine-containing tags improves biodistribution of
Vorobyeva A; Schulga A; Konovalova E; Güler R; Löfblom J; Sandström M; Garousi J; Chernov V; Bragina O; Orlova A; Tolmachev V; Deyev SM
Sci Rep; 2019 Jun; 9(1):9405. PubMed ID: 31253840
[TBL] [Abstract][Full Text] [Related]
10. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
[TBL] [Abstract][Full Text] [Related]
11. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
12. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with
Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791
[TBL] [Abstract][Full Text] [Related]
13. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
Goldstein R; Sosabowski J; Livanos M; Leyton J; Vigor K; Bhavsar G; Nagy-Davidescu G; Rashid M; Miranda E; Yeung J; Tolner B; Plückthun A; Mather S; Meyer T; Chester K
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):288-301. PubMed ID: 25391547
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [
Bragina O; Tashireva L; Loos D; Chernov V; Hober S; Tolmachev V
Pharmaceutics; 2024 Mar; 16(4):. PubMed ID: 38675107
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of
Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
[TBL] [Abstract][Full Text] [Related]
16. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
18.
Molavipordanjani S; Khodashenas S; Abedi SM; Moghadam MF; Mardanshahi A; Hosseinimehr SJ
Eur J Pharm Sci; 2020 May; 148():105312. PubMed ID: 32198014
[TBL] [Abstract][Full Text] [Related]
19. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
20. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
[No Abstract] [Full Text] [Related]
[Next] [New Search]
